STOCK TITAN
  1. Home
  2. Sec-filings
  3. ADMA
  4. [Form 4] ADMA BIOLOGICS, INC. Insider Trading Activity

ADMA Biologics (ADMA) CEO exercises options and sells 21K shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman exercised stock options for 15,000 shares of common stock at $5.40 per share on March 16, 2026, then sold 21,000 shares of common stock at $15.16 per share in open-market transactions.

The filing shows these trades were effected under a Rule 10b5-1 trading plan entered into on November 14, 2025. After the transactions, Grossman holds 2,112,777 shares of ADMA Biologics common stock directly, while entities Areth, LLC and Hariden, LLC hold 1,143,426 and 580,957 shares indirectly associated with him.

Positive

  • None.

Negative

  • None.
Insider Grossman Adam S
Role President and CEO
Sold 21,000 shs ($318K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 15,000 $0.00 --
Exercise Common Stock 15,000 $5.40 $81K
Sale Common Stock 15,000 $15.16 $227K
Sale Common Stock 6,000 $15.16 $91K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 690,950 shares (Direct); Common Stock — 2,133,777 shares (Direct); Common Stock — 1,143,426 shares (Indirect, See Footnote)
Footnotes (1)
  1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025. The price reported in Column 4 is the price at which the shares were sold. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grossman Adam S
(Last) (First) (Middle)
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17
(Street)
RAMSEY NJ 07446
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/16/2026 M 15,000(1) A $5.4 2,133,777 D
Common Stock 03/16/2026 S 15,000(1) D $15.16(2) 2,118,777 D
Common Stock 03/16/2026 S 6,000(1) D $15.16(2) 2,112,777(3)(4)(5) D
Common Stock 1,143,426 I See Footnote(6)
Common Stock 580,957 I See Footnote(7)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $5.4 03/16/2026 M 15,000(1) (8) 02/26/2034 Common Stock 15,000 $0 690,950 D
Explanation of Responses:
1. Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
2. The price reported in Column 4 is the price at which the shares were sold.
3. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
4. (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
5. (continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
6. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
7. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
8. The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact 03/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ADMA CEO Adam Grossman report on this Form 4?

Adam Grossman reported exercising options for 15,000 ADMA Biologics shares at $5.40 each and selling a total of 21,000 common shares at $15.16 per share. These actions combined an option exercise with open-market sales on March 16, 2026.

Were Adam Grossman’s ADMA share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan entered into with Fidelity Brokerage Services LLC on November 14, 2025. Such plans pre-schedule trades, providing structure and reducing the significance of trade timing decisions.

How many ADMA Biologics shares does Adam Grossman hold after these transactions?

Following the reported trades, Adam Grossman holds 2,112,777 ADMA Biologics common shares directly. In addition, Areth, LLC and Hariden, LLC, entities associated with him, hold 1,143,426 and 580,957 shares respectively, according to the holding entries and related footnotes in the filing.

What stock options did Adam Grossman exercise in the latest ADMA Form 4?

He exercised 15,000 shares from a stock option granted on February 26, 2024 with an exercise price of $5.40 per share. Footnotes explain this option vests over four years, with full vesting scheduled by February 26, 2028, subject to continued service.

At what price did Adam Grossman sell ADMA Biologics shares on March 16, 2026?

He sold a total of 21,000 ADMA Biologics common shares at a reported sale price of $15.16 per share. The Form 4 notes that this price is the amount at which the shares were sold, reflecting open-market or private sale transactions on that date.

What indirect ADMA share holdings are associated with Adam Grossman?

The filing lists 1,143,426 ADMA shares owned by Areth, LLC and 580,957 shares owned by Hariden, LLC. Footnotes state Grossman is a control person of Areth and the managing member of Hariden, so these LLCs represent indirect holdings associated with him.